Cell Cryopreservation Market - By Product Type (Cryoprotectant Agents, Equipment), Cell Type (Stem Cells, Oocytes & Embryotic Cells, Sperm Cells), Application (Drug Discovery & Development, Regenerative Medicine), End-use – Global Forecast, 2024 - 2032

Cell Cryopreservation Market Size

Cell Cryopreservation Market size was valued at USD 10.4 billion in 2023 and is estimated to expand at 21.5% CAGR from 2024 to 2032. Cell cryopreservation is a technique used to preserve cells by freezing them at extremely low temperatures, typically in liquid nitrogen, to slow down their metabolic processes and prevent deterioration.
 

Globally, public biobanks are estimated to preserve more than 800,000 units of umbilical cord blood, whereas private cord blood banks may store as many as 4 million units. The growth of the cord stem cell banking is propelled by various factors, including the rising acceptance of stem cell therapeutics, increasing R&D in the field, etc. Additionally, the market is driven by the emergence of new applications for stem cells in disease treatment, augmented investment in the management of chronic diseases, heightened awareness surrounding stem cell therapeutics, and an upswing in mergers and acquisitions involving major industry players.
 

Furthermore, ongoing advancements in biopreservation, such as improved cryoprotectants and freezing techniques, contribute to the market growth by enhancing the efficiency and viability of preserved cells. Additionally, growing investments from both public and private sectors in the life sciences and healthcare sectors contribute to the expansion of cell cryopreservation technologies and services.
 

Cell Cryopreservation Market Trends

The cell cryopreservation field is witnessing a notable trend towards the integration of automation in its processes. This advancement is contributing to more precise and reproducible results. Automated systems are playing a pivotal role in streamlining workflows, mitigating human error, and enhancing overall efficiency, particularly in the realms of cell banking and storage.
 

• Simultaneously, ongoing research efforts are dedicated to refining cryopreservation technologies. This involves the exploration and development of novel cryoprotectants and freezing techniques. The aim is to improve the viability and functionality of preserved cells, addressing challenges and optimizing the processes involved in safeguarding cellular materials for various applications in research, medicine, and biotechnology.
   
• The development of novel freezing media that optimize cell viability during the freezing and thawing process is a significant trend. These innovations aim to enhance the overall success of cryopreservation procedures.
   
• These research endeavors reflect a commitment to advancing the capabilities of cryopreservation, ultimately contributing to the broader goals of scientific and medical innovation.
   

Cell Cryopreservation Market Analysis

The market by product type is categorized into cryoprotectant agents and equipment. The equipment into garnered USD 7.5 billion revenue size in the year 2023. The equipment segment is further segmented freezers, incubators, liquid nitrogen supply tanks and cryopreservation consumables. Concurrently, there is a notable trend towards automation in cryopreservation equipment.
 

• Automated systems are gaining prominence for their ability to streamline workflows, minimize manual errors, and significantly enhance the overall efficiency of processes related to cell banking and storage.
   
• As a result, there is a rising demand for cryopreservation equipment equipped with integrated automation features. This shift underscores the industry's commitment to adopting cutting-edge technologies that not only meet the demands of biobanking but also contribute to the advancement of cryopreservation practices.
   
• The rise in biobanking activities, driven by increased demand for high-quality biological samples, directly impacts the demand for biomedical refrigerators and freezers. Biobanks utilize specialized equipment for the preservation and storage of diverse biological materials.

Based on cell type, the cell cryopreservation market unfolds its segmentation, such as stem cells, oocytes and embryotic cells, sperm cells, hepatocytes, and other cell types. The stem cells segment garnered USD 4 billion revenue size in the year 2023. Moreover, the therapeutic potential of stem cells is broad and continues to expand, contributing significantly to the growth of the stem cells segment.
 

• The development of induced pluripotent stem cells (iPSCs) has been a groundbreaking advancement. iPSCs are adult cells that have been reprogrammed to have embryonic stem cell-like properties, providing a valuable source of patient-specific cells for regenerative therapies.
   
• Stem cells, particularly neural stem cells and iPSCs, are being investigated for their potential in treating neurological conditions. This includes disorders like Parkinson's disease, Alzheimer's disease, and spinal cord injuries, where the goal is to replace damaged or lost neurons.
   
• The integration of gene editing techniques, such as CRISPR-Cas9, has revolutionized the field of stem cell research. This allows scientists to precisely modify the genetic makeup of stem cells, addressing specific genetic disorders or enhancing their therapeutic potential.

Based on application, the cell cryopreservation market is segmented into drug discovery and development, regenerative medicine, organ transplantation, clinical research, other applications. The drug discovery and development segment garnered USD 2.6 billion revenue size in the year 2023.
 

• The use of cryopreserved cell lines has become a common practice in drug discovery. Cryopreserved cells provide a stable and consistent supply of cells for high-throughput screening and other assays, ensuring reproducibility and reliability in the drug development process.
   
• Cryopreservation plays a crucial role in the development of personalized medicine. Patient-derived cells, including stem cells, can be cryopreserved for use in developing therapies tailored to individual patients. This approach is particularly relevant in oncology and other fields where personalized treatments are gaining traction.
   
• Cryopreserved cells are extensively used in preclinical studies to assess the safety and efficacy of drug candidates. The ability to cryopreserve cells ensures that researchers have a renewable source of cells for repeated experiments and long-term studies.

Based on end-use, the cell cryopreservation market unfolds its segmentation, encompassing the domains of hospitals and clinics, biotechnology and pharmaceutical companies, research and academic institutes, contract research organizations (CROs), which is estimated to account for USD 56.7 billion in 2022. The biotechnology and pharmaceutical companies segment garnered USD 3.4 billion revenue size in the year 2023.
 

• Biotechnology and pharmaceutical companies often work with specific cell lines, cultures, and primary cells for various purposes, including drug development, manufacturing, and research. Cryopreservation allows them to preserve these valuable biological materials for future use, ensuring a stable and consistent supply.
   
• They are engaged in long-term projects that require the storage of cells over extended periods. Cryopreservation allows for the long-term preservation of cells, ensuring their viability and functionality when retrieved for experiments, clinical trials, or production.
   
• In bioprocessing and manufacturing, cryopreserved cells are essential for producing biopharmaceuticals, vaccines, and other bio-based products. Cryopreservation ensures that cell lines used in large-scale production remain stable and maintain desired characteristics over time.

U.S. cell cryopreservation market accounted for USD 4.3 billion revenue size in 2023 and is predicted to witness substantial market growth over the analysis timeline.
 

• The U.S. is a global hub for biotechnology and pharmaceutical research and development. The presence of numerous biotech and pharmaceutical companies, research institutions, and academic centers conducting cutting-edge research contributes to the high demand for cell cryopreservation services and technologies.
   
• The U.S. is a leader in conducting clinical trials and drug development activities. Cell cryopreservation is crucial in these endeavors, facilitating the storage of cells for preclinical studies, clinical trials, and the development of cell-based therapies.
   
• Thus, the country's strong emphasis on research and development, coupled with a high prevalence of chronic disease, fuels continuous advancements and widespread use of these equipment’s.
   

Cell Cryopreservation Market Share

The cell cryopreservation industry is consolidated, with key players including Thermo Fisher Scientific Inc., Sartorius AG, GE Healthcare, Danaher Corporation, and others dominating the market. These companies focus on ongoing product innovation, geographical expansion, and partnerships to secure substantial market shares.
 

For instance, in July 2023, Sartorius opened a manufacturing facility for cell culture media in Puerto Rico. These media played a crucial role in producing therapeutic proteins and various modalities. This development enhanced Sartorius manufacturing capacity along with extensive portfolio, particularly in the North & South America region.
 

Cell Cryopreservation Market Companies

Some of the eminent market participants operating in the cell cryopreservation industry include:

• Thermo Fisher Scientific Inc.
• Sartorius AG
• PromoCell GmbH
• BioLife Solutions Inc.
• Merck KGaA
• HiMedia Laboratories
• Creative Biolabs
• Corning Incorporated
• GE Healthcare
• Danaher Corporation
   

Cell Cryopreservation Industry News:

• In July 2023, PromoCell, a manufacturer of cell culture products, announced the launch of PromoExQ MSC Growth Medium XF. This serum- and xeno-free cell culture medium was specifically designed to adhere to good manufacturing practice (GMP) standards, facilitating compliant maintenance, and enabling the long-term expansion of mesenchymal stem cells (MSC). This targeted product enabled the company to cater to a broader customer base, including researchers and companies involved in stem cell research, regenerative medicine, and cell therapy.
   
• In June 2023, BioLife Solutions, Inc. unveiled a new controlled-rate freezer (CRF) with a larger capacity, expanding their range of CRF products to three distinct configurations. The IntelliRate i67C, a tabletop freezer, was introduced to address a crucial client demand for enhanced volume production of cell treatments. Thus, this product launch accelerated industry expansion.
   

Cell cryopreservation market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD from 2018 to 2032 for the following segments:

Click here to Buy Section of this Report

By Product Type, 2018 – 2032 (USD Million)

• Cryoprotectant agents
  • Dimethyl sulfoxide (DMSO)
  • Ethylene glycol
  • Glycerol
  • Other agents 
• Equipment
  • Freezers
  • Incubators
  • Liquid nitrogen supply tanks
  • Cryopreservation consumables

By Cell Type, 2018 – 2032 (USD Million)

• Stem cells
• Oocytes and embryotic cells
• Sperm cells
• Hepatocytes
• Other cell types

By Application, 2018 – 2032 (USD Million)

• Drug discovery and development
• Regenerative medicine
• Organ transplantation
• Clinical research
• Other applications

By End-use, 2018 – 2032 (USD Million)

• Hospitals and clinics
• Biotechnology and pharmaceutical companies
• Research and academic institutes
• Contract research organizations (CROs)

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
• Middle East & Africa
  • Saudi Arabia
  • South Africa
  • UAE
  • Rest of Middle East & Africa